Nengwen Ke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nengwen Ke has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Ziyao Wang
Department of General Surgery, Division of Pancreatic Surgery, West China Hospital Sichuan University Chengdu China
14 shared publications- Bi-Sen Ding
Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, China
11 shared publications - Hao Kong
State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
11 shared publications - Hong Jiang
West China Hospital of Sichuan University
11 shared publications - Hubing Shi
Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China
11 shared publications - Jie Yang
Division of Pancreatic Surgery Department of General Surgery West China Hospital Sichuan University Chengdu Sichuan 610041 China scu.edu.cn
11 shared publications
Latest Publications
- 9 November 2026
- Published by Wiley in Journal of Surgical Oncology
CT‐Based Radiomics for Preoperative Prediction of Surgical Margins in Pancreatic Head Cancer: A Tool for Selecting Patients for Neoadjuvant Chemotherapy
Background: Microscopic margin involvement (≤ 1 mm) strongly predicts poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Adjuvant chemotherapy (ACT) after upfront resection fails to fully mitigate this risk. It remains uncertain whether neoadjuvant chemotherapy (NACT) can neutralize the adverse prognostic impact of impending ≤ 1 mm margins. Methods: Prognostic significance of ≤ 1 mm margins was assessed in an upfront‐resection cohort ( n = 228) using multivariable Cox regression. A separate cohort ( n = 110; 52 NACT, 58 upfront surgery) compared overall survival (OS) by margin status. A CT‐based radiomics model using a Laplacian‐Dirichlet operator was developed to predict ≤ 1 mm margins and externally validated ( n = 230). Results: ≤ 1 mm margins independently predicted worse OS vs. > 1 mm (15.0 vs. 24.0 months, p = 0.005). ACT numerically extended OS for ≤ 1 mm patients (16.0 vs. 15.0 months, p = 0.271) but did not close the survival gap. Notably, ≤ 1 mm patients receiving NACT achieved median OS of 29.4 months—comparable to > 1 mm upfront patients (31.6 months)—and significantly better than ≤ 1 mm upfront patients (19.6 months, p = 0.045). The model predicted ≤ 1 mm margins with AUCs of 0.772 (95% CI: 0.705–0.838) and 0.723 (95% CI: 0.657–0.789) in internal and external validation. Conclusion: NACT—not ACT—selectively rescues high‐risk patients destined for ≤ 1 mm margins. Our radiomics model enables preoperative identification, supporting personalized neoadjuvant therapy.
- 9 November 2026
- Published by Wiley in Journal of Surgical Oncology
CT‐Based Radiomics for Preoperative Prediction of Surgical Margins in Pancreatic Head Cancer: A Tool for Selecting Patients for Neoadjuvant Chemotherapy
Background: Microscopic margin involvement (≤ 1 mm) strongly predicts poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Adjuvant chemotherapy (ACT) after upfront resection fails to fully mitigate this risk. It remains uncertain whether neoadjuvant chemotherapy (NACT) can neutralize the adverse prognostic impact of impending ≤ 1 mm margins. Methods: Prognostic significance of ≤ 1 mm margins was assessed in an upfront‐resection cohort ( n = 228) using multivariable Cox regression. A separate cohort ( n = 110; 52 NACT, 58 upfront surgery) compared overall survival (OS) by margin status. A CT‐based radiomics model using a Laplacian‐Dirichlet operator was developed to predict ≤ 1 mm margins and externally validated ( n = 230). Results: ≤ 1 mm margins independently predicted worse OS vs. > 1 mm (15.0 vs. 24.0 months, p = 0.005). ACT numerically extended OS for ≤ 1 mm patients (16.0 vs. 15.0 months, p = 0.271) but did not close the survival gap. Notably, ≤ 1 mm patients receiving NACT achieved median OS of 29.4 months—comparable to > 1 mm upfront patients (31.6 months)—and significantly better than ≤ 1 mm upfront patients (19.6 months, p = 0.045). The model predicted ≤ 1 mm margins with AUCs of 0.772 (95% CI: 0.705–0.838) and 0.723 (95% CI: 0.657–0.789) in internal and external validation. Conclusion: NACT—not ACT—selectively rescues high‐risk patients destined for ≤ 1 mm margins. Our radiomics model enables preoperative identification, supporting personalized neoadjuvant therapy.
- 23 October 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 191 (Pt 1) , 117602
Targeted inhibition of HK2 expression in pancreatic ductal adenocarcinoma reprogrammes the immune microenvironment by regulating CCL5-mediated CD8+ T cell infiltration
- 23 October 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 191 (Pt 1) , 117602
Targeted inhibition of HK2 expression in pancreatic ductal adenocarcinoma reprogrammes the immune microenvironment by regulating CCL5-mediated CD8+ T cell infiltration
- Open Access
- 24 April 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (5) , 640
PEG-Dependent Tunable Degradation and Curcumin Release from Curcumin-Based Biomedical Polyurethanes
Curcumin, a plant-derived polyphenolic compound, exhibits diverse pharmacological activities such as antioxidant, anti-inflammatory, anticancer, neuroprotective, and cardiovascular protective effects, and is widely used in food, medicine, and other fields. However, its poor water solubility and easy oxidative degradation limit its extensive application in biomedicine. To solve these problems, a series of biomedical polyurethanes (Cur-PU) with similar molecular weights but different PEG contents were successfully synthesized using HO-PCL-OH and HO-PEG-OH as soft segments and curcumin as a chain extender. The results indicated that increasing the PEG content reduced the T1m, T1c, and H1c of Cur-PU, along with a slower crystallization rate and lower crystallinity. More importantly, a higher PEG content decreased the water contact angle but increased water solubility and water uptake, which, combined with reduced crystallinity, enhanced hydrophilicity, swelling ratio, curcumin release rate, and degradation rate in an enzymatic solution and pH 8.0 buffer. Thus, precise regulation of Cur-PU’s degradation and curcumin release was achieved by controlling the PEG content. Biocompatibility tests confirmed that Cur-PU exhibited excellent antioxidant and antibacterial activities, making it a highly promising biomedical material.
- 24 April 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (5) , 640
Open AccessPEG-Dependent Tunable Degradation and Curcumin Release from Curcumin-Based Biomedical Polyurethanes
Curcumin, a plant-derived polyphenolic compound, exhibits diverse pharmacological activities such as antioxidant, anti-inflammatory, anticancer, neuroprotective, and cardiovascular protective effects, and is widely used in food, medicine, and other fields. However, its poor water solubility and easy oxidative degradation limit its extensive application in biomedicine. To solve these problems, a series of biomedical polyurethanes (Cur-PU) with similar molecular weights but different PEG contents were successfully synthesized using HO-PCL-OH and HO-PEG-OH as soft segments and curcumin as a chain extender. The results indicated that increasing the PEG content reduced the T1m, T1c, and H1c of Cur-PU, along with a slower crystallization rate and lower crystallinity. More importantly, a higher PEG content decreased the water contact angle but increased water solubility and water uptake, which, combined with reduced crystallinity, enhanced hydrophilicity, swelling ratio, curcumin release rate, and degradation rate in an enzymatic solution and pH 8.0 buffer. Thus, precise regulation of Cur-PU’s degradation and curcumin release was achieved by controlling the PEG content. Biocompatibility tests confirmed that Cur-PU exhibited excellent antioxidant and antibacterial activities, making it a highly promising biomedical material.
- Open Access
- 14 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (1) , 17-32
Blockage of cuproplasia inhibits pancreatic tumour-associated neutrophils infiltration through TRAF6/STAT3/CCL2 pathway
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a poor prognosis and is easy to developing drug resistance to conventional therapies due to its distinctive tumour microenvironment. Recent advancements have brought attention to the aberrant copper metabolism in this malignancy, but the influence of intracellular cuproplasia and balance on the tumoral immune microenvironment is still uncertain. Methods: We analysed copper concentrations and CTR1 expression in PDAC tissues and cell lines. Spatial transcriptomics was employed to delineate the relationship between CTR1 overexpression and tumour-associated neutrophils (TANs) infiltration. Chemokine arrays and molecular assays were used to identify key signalling pathways involved. Functional experiments, including CTR1 knockdown and TRAF6 overexpression, were conducted to assess its impact on neutrophil infiltration and therapeutic synergy with gemcitabine. Results: We identified that CTR1 overexpression drives intracellular copper overaccumulation, activating TRAF6-dependent phosphorylation of JAK/STAT3. Phosphorylated STAT3 transcriptionally upregulates the chemokine CCL2, fostering CCR2-mediated TANs infiltration, which correlates with poor prognosis. Crucially, single-cell RNA sequencing revealed CTR1 knockdown suppresses a pro-metastatic TAN subpopulation (TAN-2) and dramatically reduces TANs recruitment in orthotopic tumour models. This copper-targeted intervention concurrently enhances cytotoxic CD8 + effector T cells within the TME. The translational impact is underscored in gemcitabine-resistant PDAC, where hyperactive CTR1 and intensified TANs infiltration create a therapy-refractory condition. Combining CTR1 inhibition with gemcitabine synergistically overcomes this resistance by dual remodelling of the TME. Conclusions: Our findings shed light on how intracellular copper metabolism-regulating molecules modulate the neutrophil infiltration through the TRAF6/STAT3/CCL2 pathway, and particularly, targeting the copper regulator shows potential in optimising the tumour microenvironment in the treatment of pancreatic cancers.
- 14 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (1) , 17-32
Open AccessBlockage of cuproplasia inhibits pancreatic tumour-associated neutrophils infiltration through TRAF6/STAT3/CCL2 pathway
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a poor prognosis and is easy to developing drug resistance to conventional therapies due to its distinctive tumour microenvironment. Recent advancements have brought attention to the aberrant copper metabolism in this malignancy, but the influence of intracellular cuproplasia and balance on the tumoral immune microenvironment is still uncertain. Methods: We analysed copper concentrations and CTR1 expression in PDAC tissues and cell lines. Spatial transcriptomics was employed to delineate the relationship between CTR1 overexpression and tumour-associated neutrophils (TANs) infiltration. Chemokine arrays and molecular assays were used to identify key signalling pathways involved. Functional experiments, including CTR1 knockdown and TRAF6 overexpression, were conducted to assess its impact on neutrophil infiltration and therapeutic synergy with gemcitabine. Results: We identified that CTR1 overexpression drives intracellular copper overaccumulation, activating TRAF6-dependent phosphorylation of JAK/STAT3. Phosphorylated STAT3 transcriptionally upregulates the chemokine CCL2, fostering CCR2-mediated TANs infiltration, which correlates with poor prognosis. Crucially, single-cell RNA sequencing revealed CTR1 knockdown suppresses a pro-metastatic TAN subpopulation (TAN-2) and dramatically reduces TANs recruitment in orthotopic tumour models. This copper-targeted intervention concurrently enhances cytotoxic CD8 + effector T cells within the TME. The translational impact is underscored in gemcitabine-resistant PDAC, where hyperactive CTR1 and intensified TANs infiltration create a therapy-refractory condition. Combining CTR1 inhibition with gemcitabine synergistically overcomes this resistance by dual remodelling of the TME. Conclusions: Our findings shed light on how intracellular copper metabolism-regulating molecules modulate the neutrophil infiltration through the TRAF6/STAT3/CCL2 pathway, and particularly, targeting the copper regulator shows potential in optimising the tumour microenvironment in the treatment of pancreatic cancers.
- Open Access
- 17 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1616793
Cost-effectiveness of open versus laparoscopic pancreaticoduodenectomy: a retrospective Markov model analysis from China
Introduction: Open pancreaticoduodenectomy (OPD) and laparoscopic pancreaticoduodenectomy (LPD) are the two main surgical approaches for treating pancreatic cancer. Objective: To evaluate the cost-effectiveness of OPD and LPD in treating pancreatic ductal adenocarcinoma by establishing a Markov Model. Methods: Patients with pancreatic ductal adenocarcinoma who staged at I-III undergone OPD or LPD were retrospectively included from March 2017 to December 2020. Patients were followed up by telephone until June 2024. A Markov Model was established to simulate disease progression after 120 cycles by including survival data and average hospitalization costs. Results: Two hundred patients were included, 100 for OPD group and the other 100 for LPD group. The results indicated that after 10 years of model operation, the LPD group had an increased cost of 13,175.31 yuan compared to the OPD group, with an incremental effect of 0.063 per quality-adjusted life years (QALY). It also showed that the incremental cost-effectiveness ratio value was ¥205,864.22per QALY, which was less than willing to pay (¥268,074.00). Conclusion: This study is the first to analyze the cost-effectiveness of OPD versus LPD in PDAC. The study indicated that LPD remains an acceptable operation with certain cost-effectiveness for pancreatic cancer patients. However, due to the low survival rates and the fact that LPD is a highly technique-dependent operation for pancreatic cancer, surgeons should keep cautious of the choice between the OPD and LPD based on the patient’s expectation and financial situation.
- 17 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1616793
Open AccessCost-effectiveness of open versus laparoscopic pancreaticoduodenectomy: a retrospective Markov model analysis from China
Introduction: Open pancreaticoduodenectomy (OPD) and laparoscopic pancreaticoduodenectomy (LPD) are the two main surgical approaches for treating pancreatic cancer. Objective: To evaluate the cost-effectiveness of OPD and LPD in treating pancreatic ductal adenocarcinoma by establishing a Markov Model. Methods: Patients with pancreatic ductal adenocarcinoma who staged at I-III undergone OPD or LPD were retrospectively included from March 2017 to December 2020. Patients were followed up by telephone until June 2024. A Markov Model was established to simulate disease progression after 120 cycles by including survival data and average hospitalization costs. Results: Two hundred patients were included, 100 for OPD group and the other 100 for LPD group. The results indicated that after 10 years of model operation, the LPD group had an increased cost of 13,175.31 yuan compared to the OPD group, with an incremental effect of 0.063 per quality-adjusted life years (QALY). It also showed that the incremental cost-effectiveness ratio value was ¥205,864.22per QALY, which was less than willing to pay (¥268,074.00). Conclusion: This study is the first to analyze the cost-effectiveness of OPD versus LPD in PDAC. The study indicated that LPD remains an acceptable operation with certain cost-effectiveness for pancreatic cancer patients. However, due to the low survival rates and the fact that LPD is a highly technique-dependent operation for pancreatic cancer, surgeons should keep cautious of the choice between the OPD and LPD based on the patient’s expectation and financial situation.
- Open Access
- 26 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71182
Risk Factor and Prediction Model for Malignant Transformation in Pancreatic Intraductal Papillary Mucinous Neoplasm
Purpose: Pancreatic intraductal papillary mucinous neoplasms (IPMN) are precursors to pancreatic cancer, with an increasing incidence due to advances in imaging techniques. This study aimed to identify risk factors for malignant transformation in IPMN and develop a predictive model using data from a large medical center in western China. Methods: Patients with IPMN admitted to West China Hospital between January 2010 and February 2022 were included in this study. They were divided into benign and malignant. Characteristic parameters and laboratory results were collected. The training set and test set were randomly divided at a ratio of 7:3. Least absolute shrinkage and selection operator regression was used to select potential prognostic factors. A nomogram was developed by logistic regression. Receiver operating characteristic curves and calibration curves were used to evaluate the model's predictive performance. Results: We retrospectively analyzed 182 patients, identifying six independent predictors of malignancy: classification, cyst wall thickening, abrupt changes in main pancreatic duct caliber, maximum tumor diameter, maximum main pancreatic duct diameter, and lnCA19‐9. We developed a nomogram with an area under the curve of 0.86 in the training set and 0.81 in the test set. The model showed strong predictive ability, providing a valuable tool for clinicians to guide preoperative decision‐making. Conclusion: Our study offers the first predictive model for malignant IPMN in western China and highlights the importance of comprehensive risk assessment, incorporating clinical, imaging, and laboratory data.
- 26 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71182
Open AccessRisk Factor and Prediction Model for Malignant Transformation in Pancreatic Intraductal Papillary Mucinous Neoplasm
Purpose: Pancreatic intraductal papillary mucinous neoplasms (IPMN) are precursors to pancreatic cancer, with an increasing incidence due to advances in imaging techniques. This study aimed to identify risk factors for malignant transformation in IPMN and develop a predictive model using data from a large medical center in western China. Methods: Patients with IPMN admitted to West China Hospital between January 2010 and February 2022 were included in this study. They were divided into benign and malignant. Characteristic parameters and laboratory results were collected. The training set and test set were randomly divided at a ratio of 7:3. Least absolute shrinkage and selection operator regression was used to select potential prognostic factors. A nomogram was developed by logistic regression. Receiver operating characteristic curves and calibration curves were used to evaluate the model's predictive performance. Results: We retrospectively analyzed 182 patients, identifying six independent predictors of malignancy: classification, cyst wall thickening, abrupt changes in main pancreatic duct caliber, maximum tumor diameter, maximum main pancreatic duct diameter, and lnCA19‐9. We developed a nomogram with an area under the curve of 0.86 in the training set and 0.81 in the test set. The model showed strong predictive ability, providing a valuable tool for clinicians to guide preoperative decision‐making. Conclusion: Our study offers the first predictive model for malignant IPMN in western China and highlights the importance of comprehensive risk assessment, incorporating clinical, imaging, and laboratory data.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s3 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
GO enrichment analysis of genes identified through CUT&Tag data
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s3 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
GO enrichment analysis of genes identified through CUT&Tag data
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S26 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Supplementary Fig. S1 shows representative images of human adjacent normal and PDAC tissues post-surgery, alongside representative images of Masson's trichrome staining for human adjacent normal and PDAC tissues. Supplementary Fig. S2 depicts quality control results of spatial transcriptomics, identifies cell types in human normal pancreas and PDAC tissues, and maps the spatial distribution of major cell types in sections of human adjacent normal and PDAC tissues. Supplementary Fig. S3 displays representative mIHC staining images of human adjacent normal and PDAC tissues. Supplementary Fig. S4 illustrates the mIHC staining and quantification of LYVE1+ macrophages in soft and stiff PDAC tumors. Supplementary Fig. S5 presents the mRNA expression levels of mechanosensitive ion channels and integrins in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S6 illustrates the gating strategy for bone marrow-derived monocytes and macrophages, along with representative monocyte gating in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S7 displays the quality control results of scRNA-seq data derived from human blood and PDAC samples. Supplementary Fig. S8 presents a spatiotemporal analysis of monocytes and macrophages in blood and PDAC tissues from human PDAC patients. Supplementary Fig. S9 illustrates the subcutaneous simulation of PDAC models by injecting stiff or soft hydrogels mixed with KPC cells. Supplementary Fig. S10 presents the protein expression levels of FAK in PYK2-deficient monocytes/macrophages. Supplementary Fig. S11 illustrates the influence of PYK2 on macrophage mechanotransduction in vivo. Supplementary Fig. S12 illustrates the polarization profiles of WT and Ptk2b KO BMDMs under stimulation with LPS, IL-4/IL-13, or conditioned medium. Supplementary Fig. S13 shows PYK2 deficient BMDMs exhibit impaired cell migration. Supplementary Fig. S14 illustrates the impact of PIEZO1 agonists or inhibitors on monocyte differentiation. Supplementary Fig. S15 shows the role of PYK2 as a transcriptional co-regulator in conjunction with AP-1 and/or SP-1. Supplementary Fig. S16 illustrates the effects of PYK2 deficiency in myeloid precursors on the TME and tumor growth in mouse PDAC models. Supplementary Fig. S17 displays the gating strategy and quantitative analysis of myeloid cells and lymphocytes in tissues from mouse PDAC models. Supplementary Fig. S18 presents the gating strategy and quantitative analysis of T cells within a co-culture system of T cells and monocytes/macrophages. Supplementary Fig. S19 illustrates the impact of myeloid-specific PYK2 deficiency on the TME and its enhancement of immunotherapy efficacy in mouse PDAC models. Supplementary Fig. S20 presents the quality control metrics for scRNA-seq data of PDAC tumors from WT + Iso, WT+αPD-1, Ptk2b KO + Iso and Ptk2b KO+αPD-1 groups. Supplementary Fig. S21 depicts the transcriptional profiles of monocytes, macrophages, and fibroblasts across single and combination treatment groups. Supplementary Fig. S22 shows the impact of myeloid-specific Ptk2b deficiency on fibrosis in mouse PDAC tissues. Supplementary Fig. S23 showed the distinct functional profiles of fibroblasts across experimental groups. Supplementary Fig. S24 illustrates the analysis of CD8+ T cells using flow cytometry and mIHC across single and combination treatment groups. Supplementary Fig. S25 shows the palpation-based tumor size measurements for orthotopic PDAC tumors in mice. Supplementary Fig. S26 shows the full Western blot images alongside their corresponding quantitative analyses.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S26 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Supplementary Fig. S1 shows representative images of human adjacent normal and PDAC tissues post-surgery, alongside representative images of Masson's trichrome staining for human adjacent normal and PDAC tissues. Supplementary Fig. S2 depicts quality control results of spatial transcriptomics, identifies cell types in human normal pancreas and PDAC tissues, and maps the spatial distribution of major cell types in sections of human adjacent normal and PDAC tissues. Supplementary Fig. S3 displays representative mIHC staining images of human adjacent normal and PDAC tissues. Supplementary Fig. S4 illustrates the mIHC staining and quantification of LYVE1+ macrophages in soft and stiff PDAC tumors. Supplementary Fig. S5 presents the mRNA expression levels of mechanosensitive ion channels and integrins in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S6 illustrates the gating strategy for bone marrow-derived monocytes and macrophages, along with representative monocyte gating in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S7 displays the quality control results of scRNA-seq data derived from human blood and PDAC samples. Supplementary Fig. S8 presents a spatiotemporal analysis of monocytes and macrophages in blood and PDAC tissues from human PDAC patients. Supplementary Fig. S9 illustrates the subcutaneous simulation of PDAC models by injecting stiff or soft hydrogels mixed with KPC cells. Supplementary Fig. S10 presents the protein expression levels of FAK in PYK2-deficient monocytes/macrophages. Supplementary Fig. S11 illustrates the influence of PYK2 on macrophage mechanotransduction in vivo. Supplementary Fig. S12 illustrates the polarization profiles of WT and Ptk2b KO BMDMs under stimulation with LPS, IL-4/IL-13, or conditioned medium. Supplementary Fig. S13 shows PYK2 deficient BMDMs exhibit impaired cell migration. Supplementary Fig. S14 illustrates the impact of PIEZO1 agonists or inhibitors on monocyte differentiation. Supplementary Fig. S15 shows the role of PYK2 as a transcriptional co-regulator in conjunction with AP-1 and/or SP-1. Supplementary Fig. S16 illustrates the effects of PYK2 deficiency in myeloid precursors on the TME and tumor growth in mouse PDAC models. Supplementary Fig. S17 displays the gating strategy and quantitative analysis of myeloid cells and lymphocytes in tissues from mouse PDAC models. Supplementary Fig. S18 presents the gating strategy and quantitative analysis of T cells within a co-culture system of T cells and monocytes/macrophages. Supplementary Fig. S19 illustrates the impact of myeloid-specific PYK2 deficiency on the TME and its enhancement of immunotherapy efficacy in mouse PDAC models. Supplementary Fig. S20 presents the quality control metrics for scRNA-seq data of PDAC tumors from WT + Iso, WT+αPD-1, Ptk2b KO + Iso and Ptk2b KO+αPD-1 groups. Supplementary Fig. S21 depicts the transcriptional profiles of monocytes, macrophages, and fibroblasts across single and combination treatment groups. Supplementary Fig. S22 shows the impact of myeloid-specific Ptk2b deficiency on fibrosis in mouse PDAC tissues. Supplementary Fig. S23 showed the distinct functional profiles of fibroblasts across experimental groups. Supplementary Fig. S24 illustrates the analysis of CD8+ T cells using flow cytometry and mIHC across single and combination treatment groups. Supplementary Fig. S25 shows the palpation-based tumor size measurements for orthotopic PDAC tumors in mice. Supplementary Fig. S26 shows the full Western blot images alongside their corresponding quantitative analyses.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s4 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The GO enrichment analysis results of monocyte/macrophage cell subtype markers
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s4 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The GO enrichment analysis results of monocyte/macrophage cell subtype markers